Organisation paid for research Program year 2025 Source: CMS Open Payments

Austin Regional Clinic

Neither a doctor nor a teaching hospital

Research payments

$493,320

82 payments

Through program year 2025, Austin Regional Clinic is reported as receiving $493,320 in research payments, across 82 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $229 2
2024 Research $288 2
2023 Research $27,116 9
2022 Research $62,984 30
2021 Research $87,979 6
2020 Research $125,050 9
2019 Research $189,675 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $224,587 15 payments
  2. GlaxoSmithKline, LLC. $143,503 25 payments
  3. Shire North American Group Inc $44,164 6 payments
  4. Celgene Corporation $30,300 4 payments
  5. AbbVie, Inc. $30,146 16 payments
  6. Sandoz Inc. $5,224 1 payment
  7. Eli Lilly and Company $4,315 5 payments
  8. BioCryst Pharmaceuticals, Inc. $3,500 1 payment
  9. Novartis Pharmaceuticals Corporation $2,944 1 payment
  10. Janssen Research & Development, LLC $2,700 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, $115,336 9 payments
  2. Study to Evaluate the Impact of Apremilast on MRI Outcomes in Subjects With PSA (PSA-014) $112,895 5 payments
  3. Psa-014/20200059 (Keg) (Mosaic) $58,427 2 payments
  4. Help Study Extensiontm An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Dx-2930 for Prevention Against Acute Attacks of Hereditary Angioedema Hae $44,164 6 payments
  5. Phase 2b - SLE Dose-Finding $28,957 2 payments
  6. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate $27,457 14 payments
  7. A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Active Psoriatic Arthritis (CC-10004-PSA-014) $19,100 2 payments
  8. Phase 2b SLE Dose-Finding $14,976 4 payments
  9. A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlle $12,504 2 payments
  10. (CC-99677-AS-001) Phase 2 Ankylosing Spondylitis $10,742 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record